UCB Aims To Tailor Myasthenia Gravis Therapy Options To Patients
With Two Late-Stage Candidates
Belgium’s UCB Pharma is expecting progress with new candidates for myasthenia gravis, psoriasis and osteoporosis this year.

Belgium’s UCB Pharma is expecting progress with new candidates for myasthenia gravis, psoriasis and osteoporosis this year.